Identification and characterization of epigenetic changes that control the properties of CML cells, especially those of CML stem/progenitor (lin-CD34+) cells may be useful for the design of suitable therapies for IM-refractory CML [12]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.